Switch theme
Sign up to access all valuation multiples
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
1995
131
LTM Revenue $64.3M
LTM EBITDA -$100M
-$7.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enanta Pharmaceuticals has a last 12-month revenue (LTM) of $64.3M and a last 12-month EBITDA of -$100M.
In the most recent fiscal year, Enanta Pharmaceuticals achieved revenue of $67.6M and an EBITDA of -$105M.
Enanta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enanta Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $64.3M | XXX | $67.6M | XXX | XXX | XXX |
| Gross Profit | $64.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$100M | XXX | -$105M | XXX | XXX | XXX |
| EBITDA Margin | -156% | XXX | -155% | XXX | XXX | XXX |
| EBIT | -$109M | XXX | -$122M | XXX | XXX | XXX |
| EBIT Margin | -170% | XXX | -180% | XXX | XXX | XXX |
| Net Profit | -$99.7M | XXX | -$116M | XXX | XXX | XXX |
| Net Margin | -155% | XXX | -172% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Enanta Pharmaceuticals's stock price is $6.
Enanta Pharmaceuticals has current market cap of $127M, and EV of -$7.9M.
See Enanta Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$7.9M | $127M | XXX | XXX | XXX | XXX | $-4.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Enanta Pharmaceuticals has market cap of $127M and EV of -$7.9M.
Enanta Pharmaceuticals's trades at -0.1x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Enanta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enanta Pharmaceuticals has a P/E ratio of -1.3x.
See valuation multiples for Enanta Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $127M | XXX | $127M | XXX | XXX | XXX |
| EV (current) | -$7.9M | XXX | -$7.9M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -0.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEnanta Pharmaceuticals's last 12 month revenue growth is -2%
Enanta Pharmaceuticals's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.4M for the same period.
Enanta Pharmaceuticals's rule of 40 is -158% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Enanta Pharmaceuticals's rule of X is -161% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Enanta Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -156% | XXX | -152% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | -158% | XXX | -154% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -161% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 194% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 280% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enanta Pharmaceuticals acquired XXX companies to date.
Last acquisition by Enanta Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Enanta Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Enanta Pharmaceuticals founded? | Enanta Pharmaceuticals was founded in 1995. |
| Where is Enanta Pharmaceuticals headquartered? | Enanta Pharmaceuticals is headquartered in United States of America. |
| How many employees does Enanta Pharmaceuticals have? | As of today, Enanta Pharmaceuticals has 131 employees. |
| Who is the CEO of Enanta Pharmaceuticals? | Enanta Pharmaceuticals's CEO is Dr. Jay R. Luly, PhD. |
| Is Enanta Pharmaceuticals publicy listed? | Yes, Enanta Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Enanta Pharmaceuticals? | Enanta Pharmaceuticals trades under ENTA ticker. |
| When did Enanta Pharmaceuticals go public? | Enanta Pharmaceuticals went public in 2013. |
| Who are competitors of Enanta Pharmaceuticals? | Similar companies to Enanta Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Enanta Pharmaceuticals? | Enanta Pharmaceuticals's current market cap is $127M |
| What is the current revenue of Enanta Pharmaceuticals? | Enanta Pharmaceuticals's last 12 months revenue is $64.3M. |
| What is the current revenue growth of Enanta Pharmaceuticals? | Enanta Pharmaceuticals revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Enanta Pharmaceuticals? | Current revenue multiple of Enanta Pharmaceuticals is -0.1x. |
| Is Enanta Pharmaceuticals profitable? | Yes, Enanta Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Enanta Pharmaceuticals? | Enanta Pharmaceuticals's last 12 months EBITDA is -$100M. |
| What is Enanta Pharmaceuticals's EBITDA margin? | Enanta Pharmaceuticals's last 12 months EBITDA margin is -156%. |
| What is the current EV/EBITDA multiple of Enanta Pharmaceuticals? | Current EBITDA multiple of Enanta Pharmaceuticals is 0.1x. |
| What is the current FCF of Enanta Pharmaceuticals? | Enanta Pharmaceuticals's last 12 months FCF is -$80.0M. |
| What is Enanta Pharmaceuticals's FCF margin? | Enanta Pharmaceuticals's last 12 months FCF margin is -124%. |
| What is the current EV/FCF multiple of Enanta Pharmaceuticals? | Current FCF multiple of Enanta Pharmaceuticals is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
